Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

MPN Advances Day 2019 | The challenges of post-MPN AML

Steven Knapper • 15 Nov 2019
MPN Advances Day 2019
Leukemia Myeloproliferative Neoplasms CPX-351 Venetoclax

Steven Knapper, DM, FRCPath, MRCP, BMBCh, Cardiff University, Cardiff, UK, discusses the challenges of acute myeloid leukemia (AML) that progresses from myeloproliferative neoplasms (MPNs). This interview took place at the MPN Advances Day 2019 in London, UK.

More from Steven Knapper

Challenges and perspectives on the management of AML within the UK’s NHS framework 1:35
Challenges and perspectives on the management of AML within the UK’s NHS framework
Steven Knapper • 8 Dec 2024
NCRI AML18: CPX-351 vs standard daunorubicin & cytarabine plus fractionated GO in older pts with AML 3:50
NCRI AML18: CPX-351 vs standard daunorubicin & cytarabine plus fractionated GO in older pts with AML
Steven Knapper • 8 Dec 2024
Improving treatment approaches for FLT3-mutated AML: insights into the Optimise-FLT3 trial 1:55
Improving treatment approaches for FLT3-mutated AML: insights into the Optimise-FLT3 trial
Steven Knapper • 8 Dec 2024
Developments in the treatment of patients with FLT3-mutated AML 3:26
Developments in the treatment of patients with FLT3-mutated AML
Steven Knapper • 1 May 2024

Related Videos

The value and mission of the International Workshop on Acute Leukemias 14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddock et al. • 21 Oct 2025
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years? 1:30
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years?
Koichi Takahashi • 26 Sep 2025
One big question with Naval Daver: what AML advance could transform frontline care in three years? 1:05
One big question with Naval Daver: what AML advance could transform frontline care in three years?
Naval Daver • 26 Sep 2025
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years? 3:13
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years?
Charles Craddock • 26 Sep 2025
The content of VJHemOnc is intended for healthcare professionals